Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Recent Patents on Medical Imaging

Volume 1 Issue 2
ISSN: 1877-6132
eISSN: 2210-6847


   All Titles

  Positron Emission Tomography for Future Drug Development
  pp.137-151 (15) Authors: Ryogo Minamimoto, Chumpol Theeraladanon, Akiko Suzuki, Tomio Inoue
doi: 10.2174/1877613211101020137

Productivity in the drug discovery and development process has seen a drastic decline over the last few years. Clearly, traditional approaches to drug development are not working. The new concept called “microdosing studies” was recently announced as a promising methodology for accreting drug development. The microdosing studies is a concept by administrating a low dose (microdose) of a candidate compound to human volunteers to obtain in vivo human pharmacokinetic (PK) data at an early stage of drug development. As a result unpromising candidate drugs can be eliminated at an earlier stage of drug development.

A key component for this concept is highly sensitive analytical methods such as positron emission tomography (PET), accelerator mass spectrometry (AMS) and liquid chromatography-mass spectrometry (LC/MS/MS).

This issue focuses on PET methodology from basic to future prospects for drug development and patents related to it.

  Keywords: Positron emission tomography (PET), PET/CT, drug development, microdosing, imaging, microdosing approach, primary pharmacodynamics, conventional clinical trials, accelerator mass spectrometry, liquid chromatography-mass spectrometry, non-invasive imaging, in vivo human pharmacokinetic, proton-rich isotopes, line of response, radiopharmaceutical sciences
  Affiliation: Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-ku, Tokyo, 162-8655, Japan.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2015   Bentham Science Publishers